{"nctId":"NCT00294658","briefTitle":"Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy","startDateStruct":{"date":"2006-06"},"conditions":["Myasthenia Gravis"],"count":126,"armGroups":[{"label":"Thymectomy plus prednisone","type":"ACTIVE_COMPARATOR","interventionNames":["Procedure: thymectomy plus prednisone"]},{"label":"Prednisone alone","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: prednisone alone"]}],"interventions":[{"name":"thymectomy plus prednisone","otherNames":["Extended transsternal thymectomy plus prednisone"]},{"name":"prednisone alone","otherNames":["prednisolone"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female MG patients age greater than 18 and less than 65 years\n* Onset of generalized MG within the last 5 years\n* Positive serum anti-acetylcholine receptor binding antibodies (muscle acetylcholine receptors, AchRAb =/\\> 1.00 nmol/L. AchRAb levels of 0.50-0.99 nmol/L will be acceptable if there is another confirmatory test for MG, including single-fiber electromyography (EMG), repetitive nerve stimulation, or unequivocal edrophonium testing.)\n* MGFA class II-IV at entry, using the MG Foundation of America (MGFA) classification, while receiving optimal anti-cholinesterase treatment with or without oral prednisone\n\nExclusion Criteria:\n\n* Ocular MG without generalized weakness (MGFA Class I) or minimal weakness that would not require the use of corticosteroids\n* Myasthenic weakness requiring intubation (MGFA Class IV) in the prior month\n* Immunosuppressive therapy other than corticosteroids in the preceding year\n* Medically unfit for thymectomy\n* Chest CT evidence of thymoma.\n* Pregnancy or lactation; contraindications to the use of corticosteroids, unless postmenopausal or surgically sterile. Women considering becoming pregnant during the period of the study are to be excluded.\n* A serious concurrent medical, neurological or psychiatric condition that would interfere with thymectomy or subsequent clinical assessments\n* Current alternate day dose of prednisone \\> than 1.5 mg/kg or 100 mg or the equivalent daily doses (\\> 0.75 mg/kg or 50 mg).\n* Participation in another experimental clinical trial\n* History of alcohol or drug abuse within the 2 years prior to randomization.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time-weighted Average Quantitative Myasthenia Gravis Weakness Score Over 3 Years","description":"Myasthenia Gravis (QMG) test. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease. The time weighted average is a calculation that provides an integrated measure of the outcome over the time of followup. The denominator that was used to compute the time-weighted average for the Quantitative Myasthenia Gravis (QMG) score and the prednisone dose was the number of days from randomization to the last visit. Computations used the trapezoidal method where in the QMG score is multiplied by the number of days at this level from one visit to the next and added up over the entire followup experience and divided by the total number of days from randomization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.15","spread":"4.09"},{"groupId":"OG001","value":"8.99","spread":"4.93"}]}]}]},{"type":"PRIMARY","title":"Time-weighted Average Alternate-day Prednisone Dose (mg) Measured Over 3 Years","description":"Participants reported alternate-day prednisone dose (mg) intake from baseline through withdrawn or completed 3 years follow up. The prednisone dosages had been weighted over the days of reporting period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":"23"},{"groupId":"OG001","value":"54","spread":"29"}]}]}]},{"type":"SECONDARY","title":"Subgroup Analyses of Time-weighted Average Quantitative Myasthenia Gravis Score by Prednisone Use at Enrollment","description":"Myasthenia Gravis (QMG) test. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.30","spread":"3.89"},{"groupId":"OG001","value":"9.10","spread":"5.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.66","spread":"4.79"},{"groupId":"OG001","value":"8.84","spread":"4.60"}]}]}]},{"type":"SECONDARY","title":"Subgroup Analyses of Time-weighted Average Quantitative Myasthenia Gravis Score by Sex","description":"Myasthenia Gravis (QMG) test. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.47","spread":"4.13"},{"groupId":"OG001","value":"9.73","spread":"5.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.23","spread":"3.95"},{"groupId":"OG001","value":"7.45","spread":"4.11"}]}]}]},{"type":"SECONDARY","title":"Subgroup Analyses of Time-weighted Average Quantitative Myasthenia Gravis Score by Age at Disease Onset","description":"Myasthenia Gravis (QMG) test. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.50","spread":"4.41"},{"groupId":"OG001","value":"9.60","spread":"5.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.33","spread":"2.79"},{"groupId":"OG001","value":"7.85","spread":"3.50"}]}]}]},{"type":"SECONDARY","title":"Subgroup Analyses of Time-weighted Average Alternate-day Prednisone Dose (mg) by Prednisone Use at Enrollment","description":"Participants reported alternate-day prednisone dose (mg) intake from baseline through withdrawn or completed 3 years follow up. The prednisone dosages had been weighted over the days of reporting period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":"25"},{"groupId":"OG001","value":"56","spread":"31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":"17"},{"groupId":"OG001","value":"45","spread":"22"}]}]}]},{"type":"SECONDARY","title":"Subgroup Analyses of Time-weighted Average Alternate-day Prednisone Dose (mg) by Sex","description":"Participants reported alternate-day prednisone dose (mg) intake from baseline through withdrawn or completed 3 years follow up. The prednisone dosages had been weighted over the days of reporting period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":"25"},{"groupId":"OG001","value":"54","spread":"27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":"18"},{"groupId":"OG001","value":"55","spread":"34"}]}]}]},{"type":"SECONDARY","title":"Subgroup Analyses of Time-weighted Average Average Alternate-day Prednisone Dose (mg) by Age at Disease Onset","description":"Participants reported alternate-day prednisone dose (mg) intake from baseline through withdrawn or completed 3 years follow up. The prednisone dosages had been weighted over the days of reporting period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":"25"},{"groupId":"OG001","value":"55","spread":"30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":"18"},{"groupId":"OG001","value":"49","spread":"29"}]}]}]},{"type":"SECONDARY","title":"Number of Serious Adverse Events","description":"Number of participant who experienced at least one serious adverse events over 3 years: Thymectomy plus prednisone n=25 (out of 66); Prednisone alone n=33 (out of 60)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"93","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With at Least One Serious Adverse Events","description":"Number of participant who experienced at least one serious adverse events over 3 years: Thymectomy plus prednisone n=25 (out of 66); Prednisone alone n=33 (out of 60)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]}]},{"type":"SECONDARY","title":"Classification of Serious Adverse Events","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]}]},{"type":"SECONDARY","title":"Hospitalization for Exacerbation of Myasthenia Gravis","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Number of Hospital Days","description":"Number who had hospitalization: Thymectomy plus prednisone n=15 (out of 66); Prednisone alone n=31 (out of 60)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","spread":"8.6"},{"groupId":"OG001","value":"19.2","spread":"24.5"}]}]}]},{"type":"SECONDARY","title":"Reason for Hospitalization According to Medical Dictionary for Regulatory Activities Term","description":"Number who had hospitalization: Thymectomy plus prednisone n=15 (out of 66); Prednisone alone n=31 (out of 60)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Time-weighted Average Prescribed Alternate Day Prednisone Dose (mg)","description":"Physicians reported prescribed alternate-day prednisone dose (mg) intake from baseline through withdrawn or completed 3 years follow up. The prescribed prednisone dosages had been weighted over the days of reporting period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.3","spread":"22.7"},{"groupId":"OG001","value":"55.6","spread":"29.4"}]}]}]},{"type":"SECONDARY","title":"Penalized Time-weighted Average Alternative Day Prednisone Dose (mg; Method 1: Penalized Using Maximum Dose Before Azathioprine)","description":"For each participant who took azathioprine, we penalized them by taking the maximum dose of prednisone before azathioprine was added. We then applied the same method to compute the time-weighted alternative day prednisone dose from baseline, month 3, 4, 6 and every 3 months through 36 months.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.4","spread":"28.2"},{"groupId":"OG001","value":"64.4","spread":"40.8"}]}]}]},{"type":"SECONDARY","title":"Penalized Time-weighted Average Alternative Day Prednisone Dose (mg; Method 2: Penalized Using Dose at Time of Starting Azathioprine)","description":"For each participant who took azathioprine, we penalized them by taking the prednisone dose at the time azathioprine commenced. We then applied the same method to compute the time-weighted alternative day prednisone dose from baseline, month 3, 4, 6 and every 3 months through 36 months.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":"27.2"},{"groupId":"OG001","value":"57.9","spread":"36.9"}]}]}]},{"type":"SECONDARY","title":"Time-Weighted Average MG Activity of Daily Living (MG-ADL)","description":"MG Activity of Daily Living total scores range from 0 to 24, with the lower scores indicating better daily living quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.24","spread":"2.09"},{"groupId":"OG001","value":"3.41","spread":"2.58"}]}]}]},{"type":"SECONDARY","title":"Time-Weighted Average MG Activity of Daily Living (MG-ADL) at Month 12, 24, and 36","description":"MG Activity of Daily Living total scores range from 0 to 24 by visit, with the lower scores indicating better daily living quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.92","spread":"2.73"},{"groupId":"OG001","value":"3.33","spread":"3.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.02","spread":"2.78"},{"groupId":"OG001","value":"3.11","spread":"2.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.14","spread":"2.92"},{"groupId":"OG001","value":"2.69","spread":"2.80"}]}]}]},{"type":"SECONDARY","title":"Azathioprine Use","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Plasma Exchange Use","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Intravenous Immunoglobulin Use","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Minimal Manifestation (MM) Status at Month 12, 24 and 36","description":"Number of participants who were in minimal manifestation status at month 12, 24 and 36.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Days in Hospital for Myasthenia Gravis Exacerbation","description":"Number of patients with MG exacerbation: Thymectomy plus prednisone=6 (out of 66); Prednisone alone=17 (out of 60)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"2.9"},{"groupId":"OG001","value":"26.4","spread":"28.9"}]}]}]},{"type":"SECONDARY","title":"Cumulative Days in Hospital for Myasthenia Gravis Exacerbation","description":"Number of patients with MG exacerbation: Thymectomy plus prednisone=6 (out of 66); Prednisone alone=22 (out of 60)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.7","spread":"7.7"},{"groupId":"OG001","value":"22.5","spread":"27.1"}]}]}]},{"type":"SECONDARY","title":"Short Form-36 Standardized Physical Component","description":"Range from 0 to 100, the higher the physical component value, the better the mental health.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.4","spread":null},{"groupId":"OG001","value":"37.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.4","spread":null},{"groupId":"OG001","value":"44.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.3","spread":null},{"groupId":"OG001","value":"43.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.2","spread":null},{"groupId":"OG001","value":"44.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Short Form-36 Standardized Mental Component","description":"Range from 0 to 100, the higher the mental component value, the better the mental health.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.1","spread":null},{"groupId":"OG001","value":"46.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.1","spread":null},{"groupId":"OG001","value":"41.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.9","spread":null},{"groupId":"OG001","value":"46.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.7","spread":null},{"groupId":"OG001","value":"48.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Associated Complications (TAC)","description":"Treatment associated complications measured complications occurred by myasthenia gravis patients. Report number of participant with at least one complications by each visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Associated Symptoms (TAS)","description":"Treatment associated symptoms measured myasthenia gravis symptoms such as back pain and/or bruises. Report number of participant with at least one treatment associated symptoms by each visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":25,"n":66},"commonTop":["Abnormal weight gain","Sleep disorder","Rash","Hypertension","Musculoskeletal chest pain"]}}}